Erbi Biosystems Strengthens Executive Leadership Team with Appointment of Chief Scientific Officer
BOSTON, May 31, 2022 /PRNewswire/ -- Erbi Biosystems, Inc., a global leader in dose-scale, fully automated microbioreactors for cell therapy development and manufacturing, today announced the appointment of Brad Hamilton to the position of Chief Scientific Officer, effective immediately.
- BOSTON, May 31, 2022 /PRNewswire/ -- Erbi Biosystems, Inc., a global leader in dose-scale, fully automated microbioreactors for cell therapy development and manufacturing, today announced the appointment of Brad Hamilton to the position of Chief Scientific Officer, effective immediately.
- He was previously Chief Scientific Officer at GoodCell and Chief Technology Officer at ReproCELL.
- "Brad is an exceptional scientific leader in the industry, and I am excited to have him join Erbi's executive team.
- Mr. Hamilton's scientific leadership in the industry spans more than 25 years, including his roles as the founder and Chief Scientific Officer at GoodCell and Chief Technology Officer for ReproCELL, a multinational stem cell company focused on developing novel stem cell technologies and therapies.